Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment

[FDA]

This final guidance is intended to assist sponsors in the clinical development of drugs and biological products for the treatment of AML. This guidance addresses FDA’s current thinking regarding the overall development program and clinical trial designs for AML drugs.


Baca selengkapnya di : http://www.fda.gov...